AR072239A1 - 5-[1'-(decahidro-7-hidroxi-1,1,3a,7-tetrametil-1h-ciclopropa[a]naftalen-4-il)-3'-metilbutil]-2,4,6-trihidroxi-1,3-benzenodicarboxaldehido como medicamentos - Google Patents
5-[1'-(decahidro-7-hidroxi-1,1,3a,7-tetrametil-1h-ciclopropa[a]naftalen-4-il)-3'-metilbutil]-2,4,6-trihidroxi-1,3-benzenodicarboxaldehido como medicamentosInfo
- Publication number
- AR072239A1 AR072239A1 ARP090100133A ARP090100133A AR072239A1 AR 072239 A1 AR072239 A1 AR 072239A1 AR P090100133 A ARP090100133 A AR P090100133A AR P090100133 A ARP090100133 A AR P090100133A AR 072239 A1 AR072239 A1 AR 072239A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- diseases
- disorder
- cyclopropa
- neurological
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 9
- 208000035475 disorder Diseases 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 230000000392 somatic effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 208000008811 Agoraphobia Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010024870 Loss of libido Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010034912 Phobia Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 208000037870 generalized anxiety Diseases 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- -1 opiates Natural products 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003368 psychostimulant agent Substances 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/57—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups polycyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Psychology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
Abstract
La presente se refiere a compuestos de formula (1) así como a su utilizacion como medicamentos. Preferentemente, dichos compuestos se utilizan para la preparacion de un medicamento o de un complemento alimenticio destinado al tratamiento y/o a la prevencion de las afecciones o patologías que derivan de un desorden de la recaptura de los neuromediadores siguientes: dopamina, serotonina y/o noradrenalina. Reivindicacion 1: Compuestos de formula (1') extendiéndose que las formas siguientes están excluidas: 5-[(1'R)-1'-[1aS,3aS,4S,7R,7aR,7bS)-decahidro-7-hidroxi-1,1,3a,7-tetrametil-1H-ciclopropa[a]naftalen-4-il]-3'-metilbutil]-2,4,6-trihidroxi-1,3-bencenodicarboxaldehído; y 5-[(1'S)-1'-[(1aS,3aS,4S,7R,7aR,7bS)-decahidro-7-hidroxi-1,1,3a,7-tetrametil-1H-ciclopropa[a]naftalen-4-il]-3'-metilbutil]-2,4,6-trihidroxi-1,3-bencenodicarboxaldehído. Reivindicacion 11: Utilizacion segun la reivindicacion 9, caracterizada porque la patología o la afeccion neurologica, psiquiátrica o trastorno asociado, el trastorno somático funcional o la dependencia a las sustancias adictivas se selecciona del grupo que comprende: las enfermedades neurologicas, tales como las enfermedades neurodegenerativas (enfermedad de Alzheimer, corea de Huntington, enfermedad de Parkinson, accidentes vasculares cerebrales, traumatismo craneal), la esclerosis lateral amiotrofica, las demencias seniles, las demencias fronto-temporales, las demencias vasculares, la jaqueca, los dolores neuropáticos de origen central; las enfermedades psiquiátricas, tales como la depresion (endogena, resistente, reactiva o yatrogena), el estado depresivo, la esquizofrenia, el trastorno bipolar, la ansiedad generalizada, las enfermedades ligadas al estrés, los ataques de pánico, los trastornos obsesivos compulsivos, los síndromes de estrés pos-traumáticos, los trastornos de la atencion y la hiperactividad, los trastornos de conductas alimenticias (principalmente la bulimia y la anorexia), la fobia (principalmente la agorafobia), el autismo; los trastornos de la memoria, de la atencion y de la vigilancia asociados a enfermedades, afecciones o trastornos neurologicos y psiquiátricos; los trastornos somáticos funcionales tales como el síndrome de la fatiga cronica, la fibromialgia, el síndrome del colon irritable, los reflujos gastro-esofaríngeos, la pérdida de la libido, los trastornos de la ereccion, las incontinencias urinarias; las dependencias a sustancias adictivas principalmente a la nicotina, al alcohol, a los opiáceos, a los cannabinoides y a los psicoestimulantes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800276A FR2926547B1 (fr) | 2008-01-18 | 2008-01-18 | 5-°1-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h- cyclopropa°a!naphtalen-4-yl)-3-methylbutyl!-2,4,6-trihydroxy -1,3-benzenedicarboxaldehyde en tant que medicaments. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072239A1 true AR072239A1 (es) | 2010-08-18 |
Family
ID=39764878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100133A AR072239A1 (es) | 2008-01-18 | 2009-01-16 | 5-[1'-(decahidro-7-hidroxi-1,1,3a,7-tetrametil-1h-ciclopropa[a]naftalen-4-il)-3'-metilbutil]-2,4,6-trihidroxi-1,3-benzenodicarboxaldehido como medicamentos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100286284A1 (es) |
| EP (1) | EP2230933A1 (es) |
| JP (1) | JP2011509979A (es) |
| KR (1) | KR20100103852A (es) |
| CN (1) | CN101909462A (es) |
| AR (1) | AR072239A1 (es) |
| AU (1) | AU2009220011A1 (es) |
| BR (1) | BRPI0907229A2 (es) |
| CA (1) | CA2710996A1 (es) |
| FR (1) | FR2926547B1 (es) |
| IL (1) | IL206772A0 (es) |
| MA (1) | MA31933B1 (es) |
| MX (1) | MX2010005607A (es) |
| RU (1) | RU2453527C2 (es) |
| TN (1) | TN2010000242A1 (es) |
| TW (1) | TW200944193A (es) |
| WO (1) | WO2009106769A1 (es) |
| ZA (1) | ZA201003818B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107986951B (zh) * | 2017-12-15 | 2021-04-23 | 中国科学院昆明植物研究所 | 新型拓扑异构酶i抑制剂及其药物组合物与其制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4447336C2 (de) * | 1994-12-31 | 1996-12-19 | Goebel Hartmut J Dr Med Habil | Verwendung eines Gemisches aus Cineol und Menthol |
| JP3957952B2 (ja) * | 1999-06-10 | 2007-08-15 | 花王株式会社 | セラミド産生促進剤 |
| RU2274468C2 (ru) * | 2004-06-07 | 2006-04-20 | Кубанский государственный технологический университет | Способ получения масляных экстрактов из растительного сырья |
| FR2904557B1 (fr) * | 2006-08-01 | 2010-04-30 | Pf Medicament | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques |
| EP1939166A1 (en) * | 2006-12-19 | 2008-07-02 | InterMed Discovery GmbH | Plants extracts for use in brain modulation |
-
2008
- 2008-01-18 FR FR0800276A patent/FR2926547B1/fr not_active Expired - Fee Related
-
2009
- 2009-01-13 CN CN200980101751XA patent/CN101909462A/zh active Pending
- 2009-01-13 US US12/735,457 patent/US20100286284A1/en not_active Abandoned
- 2009-01-13 WO PCT/FR2009/000038 patent/WO2009106769A1/fr active Application Filing
- 2009-01-13 KR KR1020107016622A patent/KR20100103852A/ko not_active Application Discontinuation
- 2009-01-13 BR BRPI0907229-2A patent/BRPI0907229A2/pt not_active IP Right Cessation
- 2009-01-13 CA CA2710996A patent/CA2710996A1/fr not_active Abandoned
- 2009-01-13 MX MX2010005607A patent/MX2010005607A/es not_active Application Discontinuation
- 2009-01-13 AU AU2009220011A patent/AU2009220011A1/en not_active Abandoned
- 2009-01-13 RU RU2010134420/04A patent/RU2453527C2/ru not_active IP Right Cessation
- 2009-01-13 JP JP2010542660A patent/JP2011509979A/ja not_active Abandoned
- 2009-01-13 EP EP09714176A patent/EP2230933A1/fr not_active Withdrawn
- 2009-01-16 AR ARP090100133A patent/AR072239A1/es not_active Application Discontinuation
- 2009-01-16 TW TW098101452A patent/TW200944193A/zh unknown
-
2010
- 2010-05-27 ZA ZA2010/03818A patent/ZA201003818B/en unknown
- 2010-05-28 TN TN2010000242A patent/TN2010000242A1/fr unknown
- 2010-06-22 MA MA32944A patent/MA31933B1/fr unknown
- 2010-07-01 IL IL206772A patent/IL206772A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL206772A0 (en) | 2010-12-30 |
| BRPI0907229A2 (pt) | 2015-07-14 |
| EP2230933A1 (fr) | 2010-09-29 |
| KR20100103852A (ko) | 2010-09-28 |
| AU2009220011A1 (en) | 2009-09-03 |
| MA31933B1 (fr) | 2010-12-01 |
| RU2453527C2 (ru) | 2012-06-20 |
| CA2710996A1 (fr) | 2009-09-03 |
| ZA201003818B (en) | 2011-03-30 |
| WO2009106769A1 (fr) | 2009-09-03 |
| TW200944193A (en) | 2009-11-01 |
| CN101909462A (zh) | 2010-12-08 |
| FR2926547A1 (fr) | 2009-07-24 |
| FR2926547B1 (fr) | 2010-04-23 |
| TN2010000242A1 (fr) | 2011-11-11 |
| US20100286284A1 (en) | 2010-11-11 |
| RU2010134420A (ru) | 2012-02-27 |
| MX2010005607A (es) | 2010-06-22 |
| JP2011509979A (ja) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
| DOP2013000194A (es) | Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos | |
| PH12016502231B1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
| WO2014087367A3 (en) | Compositions and methods for the treatment of neurological diseases and its associated complications | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| CL2007001023A1 (es) | Compuestos derivados de cromen-2-ona; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica, utiles para el tratamiento o prevencion de trastornos o enfermedades mediadas por los linfocitos-t, tal como artritis reumatoide y diabe | |
| BR112015027362A8 (pt) | derivados de isoquinolina estimulantes de neurogênese | |
| AR106590A1 (es) | Derivados de indolin-2-ona | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| BRPI0715691B8 (pt) | método para a produção de ácido acético | |
| RU2009107166A (ru) | Новый экстракт эвкалипта, способ его получения и его терапевтическое применение | |
| AR097088A1 (es) | Derivados de 1,7-naftiridina | |
| BR112015011094A2 (pt) | 1,6-naftiridinas substituídas | |
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
| AR072239A1 (es) | 5-[1'-(decahidro-7-hidroxi-1,1,3a,7-tetrametil-1h-ciclopropa[a]naftalen-4-il)-3'-metilbutil]-2,4,6-trihidroxi-1,3-benzenodicarboxaldehido como medicamentos | |
| BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
| AR062325A1 (es) | Inhibidor del transportador de glicina y composicion farmaceutica | |
| BR112015009990A2 (pt) | derivados de pirazina | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| AR092041A1 (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona | |
| WO2013167986A3 (en) | Compositions and methods for the treatment of epilepsy | |
| WO2012068553A3 (en) | Methods of diagnosing and treating neurodegenerative diseases | |
| WO2014057439A3 (en) | Compositions and methods for treatment of neurological diseases and its associated complications | |
| CO6771455A2 (es) | Composición de inhibidor vírico para uso terapéutico in vivo | |
| BR112013020934A2 (pt) | substâncias inibitórias do transportador de glicina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |